These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20418509)

  • 21. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model.
    Langman LJ; Shapiro AM; Lakey JR; LeGatt DF; Kneteman NM; Yatscoff RW
    Transplantation; 1996 Jan; 61(1):87-92. PubMed ID: 8560580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.
    Tang JT; de Winter BC; Hesselink DA; Sombogaard F; Wang LL; van Gelder T
    Br J Clin Pharmacol; 2017 Apr; 83(4):812-822. PubMed ID: 27753146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells.
    Albrecht W; Storck M; Pfetsch E; Martin W; Abendroth D
    Ther Drug Monit; 2000 Jun; 22(3):283-94. PubMed ID: 10850395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.
    Reine PA; Vethe NT; Kongsgaard UE; Andersen AM; Line PD; Ali AM; Bergan S
    Scand J Clin Lab Invest; 2013 Mar; 73(2):117-24. PubMed ID: 23281843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals.
    Vethe NT; Bremer S; Rootwelt H; Bergan S
    Ther Drug Monit; 2008 Dec; 30(6):647-55. PubMed ID: 18806697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.
    Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M
    Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combination of exposure to Tacrolimus, mycophenolic acid, Inosine 5'-Monophosphate Dehydrogenase activity and inhibition in the first week define early histological outcomes in renal transplant recipients.
    Thanukrishnan H; Venkataramanan R; Mehta RB; Jorgensen D; Sood P
    Clin Transplant; 2022 Dec; 36(12):e14830. PubMed ID: 36177865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients.
    Md Dom ZI; Coller JK; Carroll RP; Tuke J; McWhinney BC; Somogyi AA; Sallustio BC
    Br J Clin Pharmacol; 2018 Oct; 84(10):2433-2442. PubMed ID: 29974488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.
    Glander P; Sommerer C; Arns W; Ariatabar T; Kramer S; Vogel EM; Shipkova M; Fischer W; Zeier M; Budde K
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):503-11. PubMed ID: 20150450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients.
    Budde K; Braun KP; Glander P; Böhler T; Hambach P; Fritsche L; Waiser J; Mai I; Neumayer HH
    Transplant Proc; 2002 Aug; 34(5):1748-50. PubMed ID: 12176561
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.
    Li H; Mager DE; Sandmaier BM; Storer BE; Boeckh MJ; Bemer MJ; Phillips BR; Risler LJ; McCune JS
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1121-9. PubMed ID: 24727337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients.
    Tornatore KM; Sudchada P; Dole K; DiFrancesco R; Leca N; Gundroo AC; Danison RT; Attwood K; Wilding GE; Zack J; Forrest A; Venuto RC
    J Clin Pharmacol; 2011 Aug; 51(8):1213-22. PubMed ID: 21209244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells.
    Glander P; Sombogaard F; Budde K; van Gelder T; Hambach P; Liefeldt L; Lorkowski C; Mai M; Neumayer HH; Vulto AG; Mathot RA
    Ther Drug Monit; 2009 Jun; 31(3):351-9. PubMed ID: 19333146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.
    Bemer MJ; Risler LJ; Phillips BR; Wang J; Storer BE; Sandmaier BM; Duan H; Raccor BS; Boeckh MJ; McCune JS
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1544-52. PubMed ID: 24923537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
    Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
    Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic monitoring of mycophenolate mofetil.
    Budde K; Glander P; Bauer S; Braun K; Waiser J; Fritsche L; Mai I; Roots I; Neumayer HH
    Clin Chem Lab Med; 2000 Nov; 38(11):1213-6. PubMed ID: 11156363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus.
    Sagcal-Gironella AC; Fukuda T; Wiers K; Cox S; Nelson S; Dina B; Sherwin CM; Klein-Gitelman MS; Vinks AA; Brunner HI
    Semin Arthritis Rheum; 2011 Feb; 40(4):307-13. PubMed ID: 20655577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients.
    Molinaro M; Chiarelli LR; Biancone L; Castagneto M; Boschiero L; Pisani F; Sabbatini M; Sandrini S; Arbustini E; Tinelli C; Regazzi M; Schena FP; Segoloni GP
    Drug Metab Pharmacokinet; 2013; 28(2):109-17. PubMed ID: 22892445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.
    Riglet F; Bertrand J; Barrail-Tran A; Verstuyft C; Michelon H; Benech H; Durrbach A; Furlan V; Barau C
    Drugs R D; 2020 Dec; 20(4):331-342. PubMed ID: 33025511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.